A.R. BILALOVA¹, S.V. MOISEEVA¹, V.G. SHAKIROVA¹, I.M. KHAERTYNOVA¹, M.R. GATAULLIN ², YU.M. SOZINOVA², B.SH. FATKULLIN²

 ¹Kazan State Medical Academy, Kazan

²Republic Clinical Hospital for Infectious Diseases named after Professor A.F. Agafonov, Kazan

 Contact details:

Bilalova A.R. — PhD (medicine), Assistant Lecturer of the Infectious Diseases Department

Address: 36 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7 (843) 267-80-95, e-mail: alisa-bilalova@mail.ru

The purpose — to establish the clinical and laboratory features of COVID-19 in patients who were hospitalized at the Republic Clinical Hospital for Infectious Diseases in Kazan and to identify predictors of severe disease and death.

Material and methods. A comprehensive examination of 172 patients with coronavirus infection (COVID-19) was carried out. Patients were analyzed by gender, age, presence of vaccination against COVID-19, comorbidities, laboratory data — levels of lymphocytes, C reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer, fibrinogen, interleukin-6 (IL-6), and disease outcomes.

Results. There were no gender differences in patients with respect to the severity of COVID-19, clinical manifestations, comorbidities, or disease outcome (p > 0.05). Severe and extremely severe forms of the disease among individuals vaccinated against COVID-19 were recorded significantly less frequently (p < 0.05). The predominant symptoms of coronavirus infection were weakness, fever, headache, cough, shortness of breath. Concomitant pathology was more often recorded with severe COVID-19 than with mild (p < 0.05). At admission, all patients had lymphopenia, elevated levels of CRP, ferritin, LDH, D-dimer, fibrinogen, and IL-6, the severity of which was significantly higher in severe COVID-19 and death (p < 0.01).

Conclusion. Lymphopenia, hypofibrinogenemia, elevated levels of CRP, ferritin, LDH, IL-6, and D-dimer should be regarded as predictors of severe COVID-19 and death. Monitoring the dynamics of these blood biomarkers provides the individual approach to the management of patients with coronavirus infection.

Key words: COVID-19, clinical picture, predictors of severe COVID-19, predictors of fatal COVID-19.

REFERENCES

1. Vremennye metodicheskie rekomendatsii «Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19)», versiya 15 (22.02.2022) [Interim guidelines «Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)». Version 15 (02/22/2022)], available at: https://static-.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf
2. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly, 2020, vol. 2 (8), pp. 113–122, available at: https://www.elibrary.ru/download/elibrary_42994087_86309335.pdf
3. Sidorov V.V., Medvedeva E.A. Are there gender differences in the course of the novel coronavirus infection? Molodezhnyy innovatsionnyy vestnik, 2022, vol. 11, no. S1, pp. 214–217 (in Russ.).
4. Williamson E.J., Walker A.J., Bhaskaran K. et al. Open SAFELY: factors associated with COVID-19 death in 17 million patients. Nature, 2020, vol. 584, pp. 430–436.
5. Galiullina M.Sh., Khaliullina S.V., Khaertynov Kh.S. et al. Breakthrough infection COVID-19 according to the infectious diseases hospital. Kazanskiy meditsinskiy zhurnal, 2022, vol. 103, no. 4, pp. 541–551 (in Russ.).
6. Bahl A., Johnson S., Garcia M.H. et al. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. Lancet Reg Health Am, 2021, vol. 4, p. 100065.
7. Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA, 2020, vol. 323 (11), pp. 1061–1069.
8. Yan C.H., Faraji F., Divya P. Prajapati, et al. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol., 2020, vol. 10 (7), pp. 806–813.
9. Moein S., Hashemian M.R., Mansourafshar B., et al. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol, 2020, vol. 10 (7), pp. 944–955.
10. Li J., Wang X., Chen J., et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for Coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol, 2020, vol. 5 (7), pp. 825–830.
11. Lauer S.A., Grantz K.H., Bi Q., et al. The incubation period of Coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med, 2020, vol. 172 (9), pp. 577–582.
12. Hussain A., Bhowmik B., do Vale Moreira N.C. COVID-19 and diabetes: knowledge in progress. Diabetes Research and Clinical Practice, 2020, vol. 162, p. 108142.
13. Fei J., Fu L., Li Y. et al. Reduction of lymphocyte count at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study. Archives of Medical Science, 2020. DOI: 10.5114/aoms.2020.99006
14. Deng Y., Liu W., Liu K., et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin. Med. J. (Engl), 2020, vol. 133 (11), pp. 1261–1267.
15. Chng W.J., Lai H.C., Earnest A., Kuperan P. Haematological parameters in severe acute respiratory syndrome. Clin. Lab. Haematol, vol. 27 (1), pp. 15–20.
16. Arentz M., Yim E., Klaff L., et al. Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State. JAMA, 2020, vol. 323 (16), pp. 1612–1614.
17. Wang D., Hu B., Hu C., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, vol. 323 (11), pp. 1061–1069.
18. Tan L., Wang Q., Zhang D. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther, 2020, vol. 5, p. 33.
19. Bobylev A.A., Rachina S.A., Avdeev S.N., Dekhnich N.N. Clinical significance of the determination of C-reactive protein in the diagnosis of community-acquired pneumonia. Klin. Farmakologiya i terapiya, 2016, no. 25 (2), pp. 32–42 (in Russ.).
20. Liu F., Li L., Da Xu M., et. al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol, 2020, vol. 127, p. 104370. DOI: 10.1016/j.jcv.2020.104370
21. Deng Y., Liu W., Liu K.et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin. Med. J. (Engl), 2020, vol. 133 (11), pp. 1261–1267.
22. Chikina S.Yu., Brovko M.Yu., Royuk V.V., Avdeev S.N. Atypical course of a new coronavirus infection COVID-19 with a late increase in the level of C-reactive protein (clinical observations). Pul’monologiya, 2020, no. 30 (5), pp .709–714 (in Russ.). DOI: 10.18093/0869-0189-2020-30-5-709-714
23. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality duet COVID-19 based nan analysis of data of 150 patients from Wuhan, China. Intensive Care Med, 2020, vol. 46, pp. 846–848.
24. Berikkyzy A., Ablaykhanova N.T., Tusupbekova G.A., Kozhamzharova L.S. Influence of coronavirus on the body’s immune system Literary review. Vestnik Karagandinskogo universiteta. Seriya: Biologiya. Meditsina. Geografiya, 2022, vol. 107, no. 3, pp. 165–175 (in Russ.).
25. Ust’yantseva I.M., Zinchenko M.A., Gusel’nikova Yu.A. et al. SARS-CoV-2. Markers of inflammation. Politravma, 2020, no. 4, pp. 35–43 (in Russ.).
26. Zhilenkova Yu.I., Chernysh N.Yu. Clinical and pathogenetic significance of the determination of serum ferritin in coronavirus infection (COVID-19). Laboratornaya sluzhba, 2021, vol. 10, no. 4, pp. 41–46 (in Russ.).
27. Zhou F., Yu T., Duet R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 2020, vol. 395 (10229), pp. 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3
28. Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, 2020, p. m1091. DOI: 10.1136/bmj.m1091
29. Gómez-Pastora J., Weigand M.,Kim J., et al. Hyperferritinemia in critically ill COVID-19 patients — Is ferritin the product of inflammation or a pathogenic mediator? Clinica Chimica Acta, 2020, vol. 509, pp. 249–251. DOI: 10.1016/j.cca.2020.06.033
30. Henry B.M., de Oliveira M.H.S., Benoit S., et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM), 2020, vol. 58 (7), pp. 1021–1028.
31. Perepelitsa S.A., Kuzovlev A.N., Golubev A.M., Moroz V.V. Patent no. 2778779.C1 Rossiyskaya Federatsiya, MPK G01N 33/68, G01N 33/573, G01N 33/72. Sposob diagnostiki sindroma aktivatsii makrofagov pri novoy koronavirusnoy infektsii, vyzvannoy virusom SARS-CoV-2. no. 2022111460; Zayavl. 27.04.2022; Opubl. 24.08.2022 [Patent No. 2778779.C1 Russian Federation, IPC G01N 33/68, G01N 33/573, G01N 33/72. A method for diagnosing macrophage activation syndrome in a new coronavirus infection caused by the SARS-CoV-2 virus. No. 2022111460; Appl. 04/27/2022; Published 08/24/2022].
32. Wynants L., Van Calster B., Collins G.S., et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ, 2020, vol. 369, p. 1328.
33. Ponti G., Maccaferri M., Ruini C., et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci, 2020, vol. 57 (6), pp. 389–399.
34. Sizyakina L.P., Zakurskaya V.Ya., Skripkina N.A. et al. Clinical and immunological characteristics of moderate forms of COVID-19 at different levels of tissue destruction marker (lactate dehydrogenase). Meditsinskiy vestnik Yuga Rossii, 2021, no.  12 (4), pp. 108–115 (in Russ.).
35. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, pp. 497–506, available at: https://www.thelancet.com/article/S0140-6736(20)30183-5/fulltext
36. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb Haemost, 2020, vol. 18 (4), pp. 844–847.
37. Garrido I., Liberal R., Macedo G. Review article: COVID-19 and liver disease — what we know on 1st May 2020. Alimentary pharmacology and Therapeutics, 2020, vol. 52, pp. 267–275.
38. Huan H., Lan Y., Liu R., et al. Prominent changes in blood coagulation of patients with SARS-Cov2 infection. Clin Chem Lab Med, 2020, vol. 58 (7), pp. 1116–1120.
39. Presnyakova M.V., Galova E.A., Nekaeva E.S. et al. Hemostasiological status of patients with novel coronavirus infection COVID-19. Meditsinskiy al’manakh, 2022, no. 1 (70), pp. 37–42 (in Russ.), available at: https://cyberleninka.ru/article/n/gemostaziologicheskiy-status-patsientov-s-novoy-koronavirusnoy-infektsiey-covid-19
40. Bulanov A.Yu., Simarova I.B., Bulanova E.L. et al. New coronavirus infection COVID-19: clinical and prognostic significance of plasma fibrinogen assessment. Vestnik intensivnoy terapii imeni A.I. Saltanova, 2020, no. 4, pp. 42–47 (in Russ.), avaialble at: https://cyberleninka.ru/article/n/novaya-koronavirusnaya-infektsiya-covid-19-klinicheskaya-i-prognosticheskaya-znachimost-otsenki-fibrinogena-plazmy